A CRISPR Cholesterol Therapy Just Cleared Its First Human Safety Test

Nearly every cholesterol treatment on the market today asks the same thing of a patient: keep taking it, indefinitely. A daily statin, a biweekly PCSK9-inhibitor injection — the moment someone stops, the benefit fades. CRISPR Therapeutics has spent the last two years testing a treatment built on a different premise: edit the gene once, and the effect stays edited. The company's first full human data, presented in 2026, is the clearest evidence yet that the idea works outside a lab.

What CTX310 actually does

CTX310 is a single intravenous infusion that uses CRISPR-Cas9 to edit liver cells and switch off ANGPTL3, a gene that normally interferes with the body's ability to clear fat and cholesterol from the bloodstream. The rationale isn't new biology — people born with naturally low ANGPTL3 activity have long been observed to run unusually low cholesterol and triglyceride levels with no apparent downside, which is what made the gene an attractive editing target in the first place. What's new is doing that edit deliberately, once, in an adult liver, rather than relying on a mutation someone was born with.

The actual trial data

The Phase 1 first-in-human study dosed 15 participants (median age 53) across six sites in Australia, New Zealand, and the UK, at doses ranging from 0.1 to 0.8 mg/kg between June 2024 and August 2025. LDL cholesterol dropped by nearly 50% on average and up to 60% at the highest dose; triglycerides fell by roughly 55%. The reductions showed up within two weeks of the single infusion and held through 60 days of initial follow-up — and updated data presented at the ESC Congress in 2026 showed the LDL reduction still holding at 53% a full year after dosing, the strongest evidence so far that a single edit produces a durable, not just temporary, effect.

The reductions showed up within two weeks of a single infusion — and were still holding a year later.

The safety picture

Three participants had minor infusion-related reactions, including back pain and nausea, that resolved with medication. One participant with elevated baseline liver enzymes saw a temporary further rise that normalized without treatment. No serious long-term safety issues turned up in the data reported so far, and in line with FDA recommendations for in vivo gene-editing trials, participants will be monitored for 15 years — a reminder that "no serious issues yet" in a 15-person trial is an encouraging early signal, not a long-term safety verdict.

Why a single-dose approach actually matters

The clinical case for CTX310 isn't that it lowers cholesterol more than existing drugs — it's that it might not require a patient to keep doing anything at all. Adherence is one of the quiet, persistent failure points of cardiovascular prevention: people stop taking a daily statin, or let a biweekly injection lapse, and the protective effect disappears with it. A treatment that's administered once and, if the durability holds, keeps working without ongoing compliance would sidestep that failure mode entirely — provided the long-term safety and efficacy data continues to support it.

What's next, and the honest caveats

CRISPR Therapeutics has said Phase 2 studies are planned to test the therapy in a larger, broader patient population and confirm the durability seen so far. The caveats are real: this is still a 15-person Phase 1 trial, in vivo gene editing at scale is a young field with a limited safety track record, and — as we've covered elsewhere — even Intellia's more mature in vivo editing program hit a real safety pause in 2025 after a severe adverse event, a reminder that this class of medicine is still working through unresolved risk even as the early results look genuinely promising.